Quality requirements for allergen extracts and allergoids for allergen immunotherapy

Publication date: Available online 9 November 2017
Source:Allergologia et Immunopathologia
Author(s): J. Zimmer, A. Bonertz, S. Vieths
All allergen products for allergen immunotherapy currently marketed in the European Union are pharmaceutical preparations derived from allergen-containing source materials like pollens, mites and moulds. Especially this natural origin results in particular demands for the regulatory requirements governing allergen products. Furthermore, the development of regulatory requirements is complicated by the so far missing universal link between certain quality parameters, in particular biological potency, on the one hand and clinical efficacy on the other hand. As a consequence, each allergen product for specific immunotherapy has to be assessed individually for its quality, safety and efficacy. At the same time, biological potency of allergen products is most commonly determined using IgE inhibition assays based on human sera relative to product-specific in house references, ruling out full comparability of products from different manufacturers. This review article aims to summarize the current quality requirements for allergen products including the special requirements implemented for control of chemically modified allergen extracts (allergoids).



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2zvzsjx